Terns Pharmaceuticals, Inc. TERN
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -19.8% CAGR over 5 years.
- RSI at 78 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TERN Terns Pharmaceuticals, Inc. | 52.98 | - | $6.12B | - | -10.92% | -14.23% | - | -19.81% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 25.95M | 27.43M | 27.38M | 27.72M | 27.60M |
| Operating Income | - | -25.95M | -27.43M | -27.38M | -27.72M | -27.60M |
| EBITDA | - | -25.73M | -27.26M | -27.27M | -27.61M | -27.48M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -21.76M | -23.82M | -24.03M | -24.59M | -23.19M |
| Tax Provision | - | 40.00K | 88.00K | 64.00K | 46.00K | 383.00K |
| Net Income | - | -21.80M | -23.91M | -24.09M | -24.64M | -23.57M |
| Diluted EPS | -0.28 | -0.24 | -0.26 | -0.26 | -0.27 | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 62.03M | 102.56M | 101.87M | 110.12M |
| Operating Income | - | -62.03M | -102.56M | -101.87M | -110.12M |
| EBITDA | - | -61.00M | -101.68M | -100.97M | -109.62M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | -59.99M | -89.97M | -88.59M | -95.63M |
| Tax Provision | - | 358.00K | 239.00K | 260.00K | 581.00K |
| Net Income | - | -60.34M | -90.21M | -88.85M | -96.21M |
| Diluted EPS | -2.21 | -1.67 | -1.27 | -1.12 | - |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -19.81% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +1,505.30% |
| 6 Months: | +549.20% |
| 3 Months: | +43.88% |
| 1 Month: | +0.48% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 287.03M | 268.52M | 363.93M | 1.03B |
| Current Assets | - | 285.19M | 267.43M | 362.11M | 1.02B |
| Cash & Equivalents | - | 143.24M | 79.93M | 161.44M | 524.75M |
| Inventory | - | - | - | - | - |
| Receivables | 0 | - | - | - | - |
| Total Liabilities | - | 10.08M | 13.15M | 18.06M | 18.55M |
| Current Liabilities | - | 8.47M | 11.94M | 15.65M | 16.41M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 1.21M | 603.00K | 1.35M | 919.00K |
| Total Equity | - | 276.94M | 255.37M | 345.87M | 1.01B |
| Shares Outstanding | - | 53.72M | 64.58M | 87.13M | 112.32M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -49.11M | -67.39M | -70.02M | -82.18M |
| Investing Cash Flow | - | -22.27M | -37.99M | -12.41M | -298.04M |
| Financing Cash Flow | - | 167.09M | 41.95M | 164.00M | 743.51M |
| Capital Expenditure | -340.00K | -275.00K | -52.00K | -42.00K | - |
| Free Cash Flow | - | -49.38M | -67.44M | -70.06M | -82.18M |
| Net Change in Cash | - | 95.71M | -63.43M | 81.57M | 363.29M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -21.8% | -35.3% | -25.7% | -9.6% |
| ROCE % | - | -22.3% | -40.0% | -29.2% | -10.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.09% | 8.19M | $434.09M |
| 2 | Morgan Stanley | 6.88% | 7.95M | $420.92M |
| 3 | Adage Capital Partners GP L.L.C. | 4.80% | 5.55M | $294.01M |
| 4 | Vanguard Group Inc | 4.78% | 5.52M | $292.63M |
| 5 | Vivo Capital, LLC | 4.63% | 5.35M | $283.25M |
| 6 | Vestal Point Capital, LP | 3.90% | 4.50M | $238.39M |
| 7 | Avoro Capital Advisors LLC | 3.77% | 4.35M | $230.44M |
| 8 | Janus Henderson Group PLC | 2.93% | 3.38M | $179.03M |
| 9 | Citadel Advisors Llc | 2.74% | 3.17M | $167.75M |
| 10 | Capitolis Liquid Global Markets LLC | 2.64% | 3.05M | $161.32M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TERN